SPONSORS
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
OctOBER 28 - DAY 1
|
8:15-9:00 |
Continental Breakfast |
||||
|
8:45-9:00 |
Welcome & Announcements
Ron Dolle, PhD, Director of the Center for Drug Discovery WashU Center for Drug Discovery |
||||
|
9:00 – 10:00 |
Opening Keynote
Reimagining Drugability using Chemoproteomic Platforms Daniel Nomura, PhD University of California, Berkeley Frontier Medicine |
||||
| 10:00 - 10:30 | Coffee Break | ||||
|
10:30 - 12:00 |
Session 1: New Approach Methods (NAMs) in DDD |
||||
|
10:30 |
Pluripotent stem cell directed model of autosomal dominant polycystic kidney disease for mechanism and drug discovery Jack Song, PhD University of Alabama, Birmingham |
||||
| 11:00 |
|
||||
|
11:30 |
|
||||
|
12:00 - 1:15 |
LUNCH (included) |
||||
|
1:15 - 2:45 |
Session 2: Advancing Your Innovation |
||||
| 1:15 |
Gary Robinson, PhD NIH/NCI |
||||
|
1:45 |
 Drug Discovery and Development at WashU: The Needleman Program
Shripad Bhagwat, PhD Needleman Program for Innovation and Commercialization at WashU Medicine |
||||
| 2:15 |
D. Brian Shortel, PhD Ballard Spahr LLP |
||||
|
2:55 - 3:15 |
Coffee Break |
||||
|
3:15 - 4:15 |
Session 3: Lessons in Perseverance |
||||
|
3:15 |
The Development of mGlu4 Positive Allosteric Modulators for the Treatment of Parkinson’s Disease Colleen Niswender, PhD Vanderbilt University |
||||
| 3:45 |
Guillermo Vela, MS, BA CEO, NeuScience |
||||
|
4:15 - 4:45 |
Session 4: Posters Lightning Round Selected trainees will have 5 minutes to present their posters on stage |
||||
| 4:45 - 5:15 | Poster Mounting | ||||
|
5:15 - 7:15 |
Welcome Reception with Posters (poster judging) |
Oct. 29 - DAY 2
|
8:15 - 9:00 |
Continental Breakfast |
|
| 8:45 - 9:00 |
Welcome & Announcements
Ron Dolle, PhD Director of the Center for Drug Discovery, Washington University of St. Louis |
|
|
9:00 – 10:30 |
Session 5: Funding Sources for 2026 and Beyond |
|
|
9:00 |
The Translational Therapeutics Accelerator (TRxA): Maturing Your Academic Asset In University Walls Maaike Everts, PhD Critical Path Institute |
|
| 9:20 |
Due Diligence? What Does “Good” Look Like & How Might We Prepare? Michael Myers, PhD Associate Vice President & Head of Due Diligence, Eli Lilly & Co. |
|
| 9:40 |
Biotech Venture Capital in 2026: What do VCs look for? Ryan Sullivan, PhD Curie.Bio |
|
| 10:00 | Panel Discussion | |
| 10:30 - 11:00 |
Coffee Break |
|
|
11:00 – 11:30 |
Session 6: IMPACT Lightning Round Three 10-minute program overviews, selected from IMPACT database submissions |
|
| 11:00 |
Speaker 1 |
|
| 11:10 |
Speaker 2 |
|
| 11:20 |
Speaker 3 |
|
| 11:30 - 12:00 | Session 7: Awards & Recognitions | |
|
Paige Vinson, PhD ADDC / Southern Research |
||
| 12:00 - 1:15 |
LUNCH (included) |
|
|
1:15 - 2:15 |
Session 8: Novel Approaches to Discovery |
|
|
1:15 |
Casey Krusemark, PhD Purdue University |
|
| 1:45 |
.png)
Computationally driven drug discovery as a platform for a new generation DDC Vsevolod Katritch, PhD Professor of Quantitative & Computational Biology, Chemistry and Pharmacology, University of Southern California |
|
| 2:15 - 2:45 | Coffee Break | |
|
2:45 – 3:45 |
Closing Keynote: Learning From the Past, Looking to the Future |
|
|
Matthew D. Hall, PhD NIH/NCATS |
||
|
3:45 – 4:00 |
Closing Remarks / Adjourn
Ron Dolle, PhD Director of the Center for Drug Discovery, Washington University of St. Louis Invitation to Biogenerator Reception
Jim McCarter Sr. Managing Director, Biogenerator Ventures Sr. Vice President BioSTL |
|
| 4:30 - 6:30 | Biogenerator Startup Incubator Reception (Advance RSVP required; limited space) | at The Cortex |
|
|
Jim McCarter Sr. Managing Director, Biogenerator Ventures Sr. Vice President BioSTL |
|
|
|
KEYNOTE SPEAKERs |
|
|
